^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    ALPPL2-targeted antibody-drug conjugate

    Related drugs:
    11ms
    SGNALPV-001: A Study of SGN-ALPV in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=43, Terminated, Seagen Inc. | Trial completion date: Nov 2027 --> Dec 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Dec 2023; Study closed due to portfolio prioritization
    Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    SGN-ALPV
    1year
    SGNALPV-001: A Study of SGN-ALPV in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=43, Active, not recruiting, Seagen Inc. | Recruiting --> Active, not recruiting | N=305 --> 43
    Enrollment closed • Enrollment change • Metastases
    |
    SGN-ALPV
    over2years
    SGN-ALPV a novel, investigational vedotin ADC demonstrates highly effective targeting of oncofetal phosphatases ALPP and ALPPL2 in preclinical models (AACR 2022)
    SGN-ALPV was well tolerated in non-human primates (NHP) and exhibited linear pharmacokinetic characteristics, with a toxicity profile consistent with other vedotin-based ADCs. In summary, differential expression of ALPP and ALPPL2 in the tumor versus normal tissue, antibody specificity, antitumor activity, and tolerability of SGN-ALPV provide a strong rationale for the initiation of a planned first-in-human Phase 1 clinical study.
    Preclinical
    |
    ALPP (Alkaline Phosphatase, Placental) • ALPG (Alkaline Phosphatase)
    |
    ALPG expression
    |
    SGN-ALPV